Vaughan Nelson Investment Management L.P. Sells 33,522 Shares of Axon Enterprise, Inc $AXON

Vaughan Nelson Investment Management L.P. trimmed its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 78.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,120 shares of the biotechnology company’s stock after selling 33,522 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in Axon Enterprise were worth $3,873,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Evergreen Capital Management LLC increased its position in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Axon Enterprise by 0.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 3,968 shares of the biotechnology company’s stock worth $2,848,000 after buying an additional 19 shares during the last quarter. CWA Asset Management Group LLC boosted its holdings in shares of Axon Enterprise by 5.2% in the 4th quarter. CWA Asset Management Group LLC now owns 387 shares of the biotechnology company’s stock worth $220,000 after buying an additional 19 shares during the last quarter. Synergy Financial Group LTD grew its position in Axon Enterprise by 1.4% during the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after buying an additional 19 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Axon Enterprise by 1.2% during the second quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock valued at $1,350,000 after buying an additional 19 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Trading Down 3.2%

Shares of AXON opened at $410.03 on Tuesday. The business has a 50-day moving average of $414.43 and a 200 day moving average of $484.39. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The firm has a market cap of $33.05 billion, a P/E ratio of 164.67, a price-to-earnings-growth ratio of 7.70 and a beta of 1.45. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.90 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.47 EPS. As a group, research analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Insider Buying and Selling

In related news, President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the transaction, the president directly owned 169,125 shares in the company, valued at approximately $82,609,106.25. The trade was a 7.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CRO Cameron Brooks sold 1,242 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the sale, the executive directly owned 49,710 shares in the company, valued at $24,855,000. The trade was a 2.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 38,989 shares of company stock valued at $19,090,083. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Citizens Jmp decreased their price objective on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a report on Thursday, May 7th. UBS Group dropped their target price on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. TD Cowen reduced their target price on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. Finally, Barclays lowered their price target on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.